Home > Collections > NSTDA's Research Publications > Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
Author
Takheaw N. Jindaphun K. Pata S. Laopajon W. Kasinrerk W.
Affiliations
Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Chiang Mai 50200 Thailand; Biomedical Technology Research Center National Center for Genetic Engineering and Biotechnology National Science and Technology Development Agency Faculty of Associated Medical Sciences Chiang Mai University Chiang Mai 50200 Thailand
Type
Article
Source Title
Cells
ISSN
20734409
Year
2023
Volume
12
Issue
6
Open Access
All Open Access Gold Green
Publisher
MDPI
DOI
10.3390/cells12060848
Abstract
Cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) are components in the endocannabinoid system that play significant roles in regulating immune responses. There are many agonists for the cannabinoid receptors; however their effects on T cell regulation have not been elucidated. In the present study we determined the effects of the CB1 selective agonist ACEA and the CB2 selective agonist GW833972A on T cell responses. It was found that both agonists impaired anti-CD3 monoclonal antibody induced T cell proliferation. However ACEA and GW833972A agonists down-regulated the expression of activation markers on CD4+ and CD8+ T cells and co-stimulatory molecules on B cells and monocytes in different manners. Moreover only GW833972A suppressed the cytotoxic activities of CD8+ T cells without interfering in the cytotoxic activities of CD4+ T cells and NK cells. In addition the CB2 agonist but not CB1 agonist caused the reduction of Th1 cytokine production. Our results demonstrated that the CB1 agonist ACEA and CB2 agonist GW833972A attenuated cell-mediated immunity in different mechanisms. These agonists may be able to be used as therapeutic agents for inducing T cell hypofunction in inflammatory and autoimmune diseases. ? 2023 by the authors.